Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: Insights from MRI/PET imaging

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Methner, Carmen ^a   Buonincontri, Guido ^a   Hu, Chou I ^a   Vujic, Ana ^a   Kretschmer, Axel ^b   Sawiak, Stephen ^a   Carpenter, Adrian ^a   Stasch, Johannes Peter ^b   Krieg, Thomas ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOBUTROL; PLACEBO; RIOCIGUAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOLUS INJECTION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE MASS; HEART PROTECTION; IMAGE ANALYSIS; LEFT CORONARY ARTERY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY; GUANYLATE CYCLASE; HEART FAILURE; HEMODYNAMICS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84896704636     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083910     Document Type: Article

References (28)

1. Ertl G, Frantz S (2005) Healing after myocardial infarction. Cardiovasc Res 66: 22-32. (Pubitemid 40360705)
2. Maas O, Donat U, Frenzel M, Rütz T, Kroemer HK, et al. (2008) Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG. Br J Pharmacol 154: 25-31. (Pubitemid 351620400)
3. ATP channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol 42: 453-458.
4. Krieg T, Liu Y, Rütz T, Methner C, Yang X-M, et al. (2009) BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically postconditions rabbit and rat hearts. Eur Heart J 30: 1607-1613.
5. Burley DS, Baxter GF (2007) B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol 102: 529-541. (Pubitemid 47578398)
6. Methner C, Lukowski R, Grube K, Loga F, Smith RAJ, et al. (2013) Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G. Basic Res Cardiol 108: 337.
7. Sun J, Aponte AM, Kohr MJ, Tong G, Steenbergen C, Murphy E (2013) Essential role of nitric oxide in acute ischemic preconditioning: S-Nitros(yl)ation versus sGC/cGMP/PKG signaling? Free Radic Biol Med 54: 105-112.
8. Sun J, Murphy E (2010) Protein S-nitrosylation and cardioprotection. Circ Res 106: 285-296.
9. Prime TA, Blaikie FH, Evans C, Nadtochiy SM, James AM, et al. (2009) A mitochondria-targeted S-nitrosothiol modulates respiration, nitrosates thiols, and protects against ischemia-reperfusion injury. Proc Natl Acad Sci USA 106: 10764-10769.
10. Tse MT (2012) Phase III success for first-in-class pulmonary hypertension drug. Nat Rev Drug Discov 11: 896.
11. Ghofrani H-A, Galiè N, Grimminger F, Grünig E, Humbert M, et al. (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369: 330-340.
12. Ghofrani H-A, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, et al. (2013) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369: 319-329.
13. Stasch J-P, Pacher P, Evgenov OV (2011) Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123: 2263-2273.
14. Geschka S, Kretschmer A, Sharkovska Y, Evgenov OV, Lawrenz B, et al. (2011) Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One 6: e21853.
15. Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann LS, et al. (2010) Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens 28: 1666-1675.
16. Schmidt K, Tissier R, Ghaleh B, Drogies T, Felix SB, Krieg T (2010) Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion. Eur Heart J 31: 1655-1662.
17. Gilson WD, Yang Z, French BA, Epstein FH (2005) Measurement of myocardial mechanics in mice before and after infarction using multislice displacement-encoded MRI with 3D motion encoding. Am J Physiol Heart Circ Physiol 288: H1491-H1497. (Pubitemid 40270061)
18. Epstein FH, Gilson WD (2004) Displacement-encoded cardiac MRI using cosine and sine modulation to eliminate (CANSEL) artifact-generating echoes. Magn Reson Med 52: 774-781. (Pubitemid 39314979)
19. Buonincontri G, Methner C, Krieg T, Carpenter TA, Sawiak SJ (2013) A fast protocol for infarct quantification in mice. J Magn Reson Imaging 38: 468-473.
20. Hawkes RC, Fryer TD, Siegel S, Ansorge RE, Carpenter TA (2010) Preliminary evaluation of a combined microPET-MR system. Technol Cancer Res Treat 9: 53-60.
21. Heiberg E, Sjögren J, Ugander M, Carlsson M, Engblom H, Arheden H (2010) Design and validation of Segment - freely available software for cardiovascular image analysis. BMC Med Imaging 10: 1.
22. Flynn TJ (1997) Two-dimensional phase unwrapping with minimum weighted discontinuity. J Opt Soc Am 14: 2692-2701.
23. Sawiak SJ, Wood NI, Williams GB, Morton AJ, Carpenter TA (2009) Voxel-based morphometry in the R6/2 transgenic mouse reveals differences between genotypes not seen with manual 2D morphometry. Neurobiol Dis 33: 20-27.
24. Stegger L, Hoffmeier A-N, Schäfers KP, Hermann S, Schober O, et al. (2006) Accurate noninvasive measurement of infarct size in mice with high-resolution PET. J Nucl Med 47: 1837-1844. (Pubitemid 47545006)
25. Ott IM, Alter ML, von Websky K, Kretschmer A, Tsuprykov O, et al. (2012) Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade. PLoS One 7: e42623.
26. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, et al. (1971) Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43: 67-82.
27. Maroko PR, Braunwald E (1976) Effects of metabolic and pharmacologic interventions on myocardial infarct size following coronary occlusion. Circulation53(3 Suppl): 162-168.
28. Hung CL, Verma A, Uno H, Shin SH, Bourgoun M, et al. (2010) Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol 56: 1812-1822.